Navigation Links
ViroPharma Receives Complete Response Letter for Cinryze(TM) Supplemental Biologics License Application for Acute Treatment of Hereditary Angioedema
Date:6/4/2009

- Company Also Granted Expansion of Prophylaxis Therapy Label to Include Patient Labeling for Self-Administration -

EXTON, Pa., June 4 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that it has received a Complete Response letter from the U.S. Food and Drug Administration (FDA) related to its supplemental Biologics License Application (sBLA) for Cinryze(TM) (C1 esterase inhibitor [human]) as a treatment for acute attacks of hereditary angioedema (HAE). The FDA has requested an additional clinical study, due to their opinion that the placebo controlled study submitted in support of the sBLA lacked robustness. In the Complete Response letter, the FDA cited no safety concerns related to acute treatment with Cinryze in the clinical studies.

In addition, ViroPharma announced that FDA has approved the patient labeling for Cinryze to include self-administration for routine prophylaxis, once patients are properly trained by their healthcare provider.

"Though Cinryze is already successfully preventing attacks of HAE in many patients, there remains an unmet medical need for patients suffering from acute laryngeal attacks," said Vincent Milano, ViroPharma's president and chief executive officer. "Despite having a statistically significant result using the most conservative intent-to-treat (ITT) analysis, the FDA feels that the data are not robust enough to support approval at this time. We intend to respond to the FDA about our plans, and we will provide an update on the second quarter financial call."

In October 2008, Cinryze was approved as the first and only targeted therapy for routine prophylaxis against angioedema attacks. In clinical studies and in commercial use, Cinryze has been generally well-tolerated. In the controlled clinical trials of Cinryze, there we
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ViroPharma to Present at Two June Healthcare Conferences
2. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
3. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
4. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
5. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma to Present at Three November Healthcare Conferences
8. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
9. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
10. ViroPharma to Present at Three October Healthcare Conferences
11. ViroPharma to Present at Three September Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 A new report by  ... will reach $22.4bn in 2019. That revenue forecast and ... Market Prospects 2015-2025 ,  published in March ... to provide forecasts and qualitative analyses of the antithrombotic ... consultancy in London, UK . It ...
(Date:5/1/2015)... TRIANGLE PARK, N.C. , May 1, 2015  United ... Roger Jeffs , Ph.D., President and Co-Chief Executive Officer of ... company,s business at the Deutsche Bank 40 th Annual ... The presentation will take place on Wednesday, May ... accessed via a live webcast on the United Therapeutics website ...
(Date:4/30/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) reported total research ... $4.4 million, compared to $8.0 million during the same period ... was $8.9 million, or $0.23 per basic and diluted share. ... period in 2014, of $8.7 million, or $0.27 per basic ... cash equivalents and investments totaled $117.5 million. , "During ...
(Date:4/30/2015)... NEW YORK , April 30, 2015 The ... the Board of Directors of China Cord Blood Corp (NYSE: ... that the special committee of the independent directors of China ... extremely low privatization offer of $6.40 per share from Golden ... transaction at $6.40 per share would greatly benefit Golden Med ...
Breaking Biology Technology:Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 2Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 3Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 4Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 5Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 6Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 7Cytokinetics, Incorporated Reports First Quarter 2015 Financial Results 8April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5
... , SAN DIEGO, Dec. 9 Neurocrine ... and safety results from the Tulip PETAL Study (703 Study), ... nonpeptide Gonadotropin-Releasing Hormone (GnRH) receptor antagonist, elagolix, in patients with ... the Tulip PETAL Study are consistent with what we have ...
... ... 7.0 Data Management Platform for High Throughput and High Content Screening. , ... Basel, Switzerland and Granada, Spain ... solutions for drug discovery and life science research, and Fundación MEDINA (Centro ...
... ... Sciences Division , ... Beijing, China (PRWEB) December 9, 2009 -- China-based CSOFT International Ltd., a leading provider ... for the global market, announced today the hiring of Tammy Werner as Director of ...
Cached Biology Technology:Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 2Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 3Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 4Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 5Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain 6MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 2MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 3MEDINA Scientists Select Genedata Screener for Lead Discovery from Natural Products 4CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 2CSOFT's MedL10N Hires Beckman Coulter Veteran Tammy Werner 3
(Date:4/27/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces that its Wocket® ... first week of May, 2015 and will be fulfilling ... Gino Pereira , Chief Executive Officer ... as Wocket® enters the consumer market. We would like ...
(Date:4/21/2015)... 21, 2015 High crime ... are boosting access control systems market in ... a recently published report by TechSci Research " Saudi ... access control systems market in Saudi Arabia ... 2020.The access control systems market in the Kingdom is ...
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3
... and other human-driven factors could pit savannas and forests ... Princeton University researchers to stabilize the two. Without this ... one other to the detriment of the people and ... reported this month in the journal Science ...
... Environment and Health today published a study of ... declarations from eleven UN conferences on water and ... deepening and shallowing of key terms were evident ... strategies for highlighting and strengthening key concepts. ...
... October 31, 2011 - It has long been thought ... damage to the optic nerves leads to permanent impairments ... orientation. A new study published in Elsevier,s Brain ... levels of non-invasive, repetitive, transorbital alternating current stimulation (rtACS) ...
Cached Biology News:Savannas, forests in a battle of the biomes, Princeton researchers find 2Savannas, forests in a battle of the biomes, Princeton researchers find 3Savannas, forests in a battle of the biomes, Princeton researchers find 4Deep words, shallow words: An initial analysis of water discourse in 40 years of UN declarations 2Noninvasive current stimulation improves sight in patients with optic nerve damage 2
... Application: Pyronin Y is most ... green to selectively and differentially stain ... In a dichromatic dye solution, Pyronin ... green stains DNA green. ...
... is designed for the fast and simple ... at any position (for the generation of ... is designed to allow neomycin / kanamycin ... combines a prokaryotic promoter (gb2) for expression ...
... the first instrument to offer true walk-away automation ... to isolate cells by either positive or negative ... 4 samples at one time. RoboSep is easily ... graphical user interface makes it simple and fast ...
Plasmid expressing the LacZ reporter gene....
Biology Products: